论文部分内容阅读
目的:确定131I标记的抗原-14F(双体)[131I-MN-14F(ab)2]治疗甲状腺髓样癌(MTC)的最大耐受剂量(MTD),并收集在这个剂量下早期疗效的资料。方法:依据组织学、放射学或血浆降钙素水平的升高选择15例确诊为MTC病人(男10例、女5例,中位数年龄51岁)。12例为散发,3例为家族性。所有病?
OBJECTIVE: To determine the maximum tolerated dose (MTD) of 131I-labeled antigen-14F (dual) [131I-MN-14F (ab) 2] for treatment of medullary thyroid carcinoma (MTC) and to collect early treatment effects at this dose data. Methods: Fifteen patients diagnosed as MTC (10 males and 5 females with a median age of 51 years) were selected based on histology, radiology or plasma calcitonin levels. 12 cases were sporadic and 3 cases were familial. All diseases?